Gilphex TR

Product NDC
58552-313
11-digit product format
585520313
Labeler code
58552
Product ID
58552-313_b6a0f6e2-7b3d-6192-e053-2a95a90aa6a0
Type
HUMAN OTC DRUG
Nonproprietary name
Guaifenesin and Phenylephrine HCl
Dosage form
TABLET, FILM COATED
Route
ORAL
Labeler
Gil Pharmaceutical Corp
Application
part341
Marketing category
OTC MONOGRAPH FINAL
Marketing start
2008-02-12
Marketing end
0000-00-00
Substance
GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
Active strength
388 mg/1; mg/1
NDC exclude flag
No
Listing certified through
2021-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 3 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct58552-313DDiscontinued by firm2026-11-16
excluded packagepackage58552-31358552-313-01DDiscontinued by firm2026-11-16
excluded packagepackage58552-31358552-313-02DDiscontinued by firm2026-11-16

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 45 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCCodeStatusSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductDDiscontinued by firmd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage58552-313-02DDiscontinued by firmd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage58552-313-01DDiscontinued by firmd630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductDDiscontinued by firmf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage58552-313-02DDiscontinued by firmf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage58552-313-01DDiscontinued by firmf5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproductIInactivated by FDA2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage58552-313-01IInactivated by FDA2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage58552-313-02IInactivated by FDA2ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproductIInactivated by FDAa1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage58552-313-01IInactivated by FDAa1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage58552-313-02IInactivated by FDAa1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductIInactivated by FDAcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage58552-313-01IInactivated by FDAcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage58552-313-02IInactivated by FDAcfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductIInactivated by FDAcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage58552-313-01IInactivated by FDAcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage58552-313-02IInactivated by FDAcdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproductIInactivated by FDA302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage58552-313-01IInactivated by FDA302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage58552-313-02IInactivated by FDA302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproductIInactivated by FDAed331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage58552-313-01IInactivated by FDAed331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage58552-313-02IInactivated by FDAed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproductIInactivated by FDA0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage58552-313-01IInactivated by FDA0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage58552-313-02IInactivated by FDA0efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductIInactivated by FDAad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage58552-313-01IInactivated by FDAad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage58552-313-02IInactivated by FDAad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproductIInactivated by FDA367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage58552-313-01IInactivated by FDA367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage58552-313-02IInactivated by FDA367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproductIInactivated by FDA557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage58552-313-01IInactivated by FDA557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage58552-313-02IInactivated by FDA557ba5c1ecfa…9c80585c8c6e…
2024-05-28 21:12 UTC · source 2024-05-28excluded productproductIInactivated by FDA8af77b9d5b6f…d9bbb34c5368…
2024-05-28 21:12 UTC · source 2024-05-28excluded packagepackage58552-313-01IInactivated by FDA8af77b9d5b6f…d9bbb34c5368…
2024-05-28 21:12 UTC · source 2024-05-28excluded packagepackage58552-313-02IInactivated by FDA8af77b9d5b6f…d9bbb34c5368…
2024-05-15 03:39 UTC · source 2024-05-14excluded productproductIInactivated by FDA834df4deac94…adcc014656a3…
2024-05-15 03:39 UTC · source 2024-05-14excluded packagepackage58552-313-01IInactivated by FDA834df4deac94…adcc014656a3…
2024-05-15 03:39 UTC · source 2024-05-14excluded packagepackage58552-313-02IInactivated by FDA834df4deac94…adcc014656a3…
2024-03-11 06:39 UTC · source 2024-03-08excluded productproductIInactivated by FDA1332a3947898…d4bfe170f9cd…
2024-03-11 06:39 UTC · source 2024-03-08excluded packagepackage58552-313-01IInactivated by FDA1332a3947898…d4bfe170f9cd…
2024-03-11 06:39 UTC · source 2024-03-08excluded packagepackage58552-313-02IInactivated by FDA1332a3947898…d4bfe170f9cd…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDCEffectiveRelated label
58552-313-012025-06-264062-Gil
58552-313-022025-06-264062-Gil
58552-313-012023-01-304062-Gil
58552-313-022023-01-304062-Gil

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
58552-313-01EA - Each58552-3135bde9455-ed97-4b64-8f35-9c12de07ae4d12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
GUAIFENESINACTIVE INGREDIENT495W7451VQGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
PHENYLEPHRINE HYDROCHLORIDEACTIVE INGREDIENT04JA59TNSJGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
GUAIFENESINACTIVE MOIETY495W7451VQGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
PHENYLEPHRINEACTIVE MOIETY1WS297W6MVGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61UGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
CROSCARMELLOSE SODIUMINACTIVE INGREDIENTM28OL1HH48GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
HYPROMELLOSE 2910 (6 MPA.S)INACTIVE INGREDIENT0WZ8WG20P6GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
LACTOSEINACTIVE INGREDIENTJ2B2A4N98GGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
MAGNESIUM SILICATEINACTIVE INGREDIENT9B9691B2N9GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I30GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
MALTODEXTRININACTIVE INGREDIENT7CVR7L4A2DGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
MINERAL OILINACTIVE INGREDIENTT5L8T28FGPGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
POLYETHYLENE GLYCOL 400INACTIVE INGREDIENTB697894SGQGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
POVIDONE K30INACTIVE INGREDIENTU725QWY32XGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU4GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
SODIUM LAURYL SULFATEINACTIVE INGREDIENT368GB5141JGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65APGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JPGILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2
TRIACETININACTIVE INGREDIENTXHX3C3X673GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET [GIL PHARMACEUTICAL CORP]2

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
58552-313GILPHEX TR (GUAIFENESIN AND PHENYLEPHRINE HCL) TABLET, FILM COATED [GIL PHARMACEUTICAL CORP]4Legacy NDC20201231_80a33cba-9577-402a-84bc-1507c439c933.zip

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
58552-313-0158552031301100 TABLET, FILM COATED in 1 BOTTLE (58552-313-01) 2011-05-130000-00-00NoNoCurrent
58552-313-025855203130212 BLISTER PACK in 1 CARTON (58552-313-02) > 2 TABLET, FILM COATED in 1 BLISTER PACK12 blister pack2011-07-150000-00-00YesNoCurrent